PT-141 (Bremelanotide)

PT-141 (Bremelanotide)

Research use only. This content is for educational purposes and is not medical advice. PT-141 is a prescription drug in some jurisdictions. Do not use without qualified medical supervision.

Description

PT-141 (bremelanotide) is a melanocortin receptor agonist (primarily MC4R activity) developed for sexual dysfunction. Clinically, bremelanotide is FDA-approved (brand: Vyleesi) for premenopausal hypoactive sexual desire disorder (HSDD). Unlike PDE5 inhibitors, PT-141 works centrally (brain pathways) rather than directly on penile vasodilation.

Mechanism (high level): Melanocortin receptor activation can modulate sexual desire/arousal signaling and autonomic outflow. Effects may occur in both men and women.

Potential Benefits (as studied)

  • Improved sexual desire and reduced distress in women with HSDD (clinical trials).
  • Increased arousal response in some study settings.
  • Possible utility in select erectile dysfunction contexts (research/clinical investigation).
  • Central mechanism may benefit individuals who do not respond to PDE5 inhibitors (research context).

Side Effects

  • Nausea (common; can be dose-limiting).
  • Flushing and warmth.
  • Headache.
  • Increased blood pressure / decreased heart rate (transient).
  • Injection site reactions (if subcutaneous).
  • Hyperpigmentation with repeated use has been reported for melanocortin agonists.

Contraindications / Who Should Avoid

  • Uncontrolled hypertension or known cardiovascular disease risk where transient BP increases are unsafe.
  • Pregnancy or breastfeeding (avoid; insufficient safety data).
  • Concomitant drugs where BP/HR changes are a concern (medical review required).
  • History of severe nausea/vomiting with melanocortin agonists.

Dosing Protocols (Research/Reference)

On-demand (common clinical reference)

  • 1.75 mg subcutaneous ~45 minutes before anticipated sexual activity (typical label reference for bremelanotide).
  • Do not exceed 1 dose within 24 hours and 8 doses/month (label reference; discuss with clinician).

Reconstitution (if supplied as lyophilized vial)

  • Use bacteriostatic water (common research practice) and aseptic technique.
  • Example: add 1.0 mL to a 10 mg vial → concentration 10 mg/mL.
  • At 10 mg/mL, a 1.75 mg dose = 0.175 mL (17.5 IU on a U-100 insulin syringe).
  • Store reconstituted vial refrigerated; discard per sterility best practices.

Mitigating nausea (reference ideas)

  • Consider dose timing with food per clinician guidance.
  • Some protocols explore lower test doses first (medical supervision).
  • Hydration and avoiding alcohol may reduce adverse effects in some people.
Note: Many “peptide” PT-141 products are not FDA-regulated. Potency/sterility can vary. Clinical bremelanotide is prescription-only.

Stacking Suggestions (Research Context)

  • PT-141 is often discussed alongside PDE5 inhibitors (e.g., sildenafil) in research conversations; any combination should be clinician-supervised due to blood pressure considerations.
  • Lifestyle foundations (sleep, stress management) often have outsized effect vs. stacking multiple compounds.

Research Sources (PubMed)

  1. Kingsberg SA et al. Obstet Gynecol. 2019. PMID: 31779145
  2. Clayton AH et al. J Sex Med. 2019. PMID: 31571272
  3. Derogatis LR et al. J Womens Health (Larchmt). 2019. PMID: 30953309
  4. Diamond LE et al. J Sex Med. 2011. PMID: 21452101
  5. Wessells H et al. J Urol. 2006. PMID: 16870167
  6. Dorr RT. Clin Pharmacol Ther. 2000. PMID: 10840086
Scroll to Top